GO-203-2c regulatory update

FDA granted Orphan Drug designation for Genus' GO-203-2c to treat pancreatic cancer. The peptide that blocks the ability of mucin 1 ( MUC1; CD227) to oligomerize is in Phase I testing to treat advan...